Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines, Inc. ( (PRAX)) has released its Q2 earnings. Here is a breakdown of the information Praxis Precision Medicines, Inc. presented to its investors. Take advantage of TipRanks ...

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...

(RTTNews) - Praxis Precision Medicines, Inc. (PRAX) issued an update on Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with Photo Paroxysmal Response, or PPR. In the 45 mg ...